Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study

Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study

The cytolethal distending toxin (CDT), <i>Haemophilus ducreyi</i>, is one of the bacterial toxins that have recently been considered for targeted therapies, especially in cancer therapies. CDT is an A-B2 exotoxin. Its catalytic subunit (CdtB) is capable of inducing DNA double strand brea...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Maryam Keshtvarz, Mahdieh Mahboobi, Marek Kieliszek, Antoni Miecznikowski, Hamid Sedighian, Milad Rezaei, Mohammad Ali Haghighi, Zahra Zareh, Ehsan Rezaei
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
cytolethal distending toxin
immunogenicity
stability
tumor therapy
mutation
Medicine
R
Acceso en línea:https://doaj.org/article/148446ce389d4c62b5445fcaf8876908
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares